What is the recommended treatment for an uncomplicated urinary tract infection (UTI) and acute bacterial sinusitis in a non‑pregnant adult with normal renal function, considering penicillin allergy status and possible renal impairment?

Treatment Management for UTI and Sinusitis

Uncomplicated Urinary Tract Infection (UTI)

First-Line Oral Antibiotics for Non-Pregnant Adults with Normal Renal Function

Nitrofurantoin 100 mg orally twice daily for 5 days is the preferred first-line agent for uncomplicated cystitis in adults with normal renal function (eGFR ≥30 mL/min/1.73 m²). This regimen achieves approximately 93% clinical cure and 88% microbiological eradication, with worldwide resistance rates below 1%, and causes minimal disruption to intestinal flora compared with fluoroquinolones or broad-spectrum agents. 1

• Trimethoprim-sulfamethoxazole (TMP-SMX) 160/800 mg orally twice daily for 3 days should be used only when local E. coli resistance is <20% and the patient has not received TMP-SMX in the preceding 3 months; this regimen provides approximately 93% clinical cure and 94% microbiological eradication when the pathogen is susceptible. 1

• Fosfomycin trometamol 3 g as a single oral dose offers approximately 91% clinical cure with therapeutic urinary concentrations maintained for 24–48 hours and initial-infection resistance rates around 2.6%; it is particularly useful when TMP-SMX resistance exceeds 20% in the community. 1

Penicillin Allergy Considerations

• For patients with documented penicillin allergy, nitrofurantoin or fosfomycin remain the preferred first-line options because they completely avoid both sulfonamide and penicillin classes. 1

• All beta-lactam antibiotics (amoxicillin, amoxicillin-clavulanate, cephalosporins) are contraindicated in patients with penicillin allergy due to potential cross-reactivity. 1

Renal Impairment Adjustments

• Nitrofurantoin must be avoided when eGFR <30 mL/min/1.73 m² because adequate urinary concentrations cannot be achieved. 1

• Fosfomycin can be used at standard dosing without adjustment for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m²); however, patients with hypernatremia, cardiac insufficiency, or severe renal insufficiency should use it with caution. 1

Reserve (Second-Line) Agents – Use Only When First-Line Fails

• Fluoroquinolones (ciprofloxacin 250–500 mg twice daily or levofloxacin 250–750 mg once daily for 3 days) should be reserved exclusively for culture-proven resistant pathogens or documented failure of first-line agents because serious adverse effects (tendon rupture, peripheral neuropathy, CNS toxicity) outweigh benefits in uncomplicated cystitis. 1

• Beta-lactams (amoxicillin-clavulanate, cefdinir, cefpodoxime for 3–7 days) achieve only 89% clinical cure and 82% microbiological eradication, which is significantly inferior to first-line agents; amoxicillin or ampicillin alone should never be used because worldwide E. coli resistance exceeds 55–67%. 1

Diagnostic Recommendations

• Routine urine culture is not required for otherwise healthy women presenting with typical lower urinary symptoms (dysuria, frequency, urgency) in the absence of vaginal discharge. 1

• Obtain urine culture and susceptibility testing when any of the following occur:

  • Persistent symptoms after completing the prescribed regimen 1
  • Recurrence of symptoms within 2–4 weeks 1
  • Fever >38°C, flank pain, or costovertebral angle tenderness suggesting pyelonephritis 1
  • Atypical presentation or presence of vaginal discharge 1
  • History of recurrent infections or prior isolation of resistant organisms 1

Management of Treatment Failure

• If symptoms persist after 2–3 days or recur within 2 weeks, obtain a urine culture and susceptibility testing immediately and switch to a different antibiotic class for a full 7-day course (not the original short regimen). 1

• Assume the original pathogen is resistant to the previously used agent when retreating. 1

Critical Pitfalls to Avoid

• Do not treat asymptomatic bacteriuria in non-pregnant, non-catheterized women, as this promotes resistance without clinical benefit. 1

• Do not prescribe TMP-SMX without confirming that local E. coli resistance is <20%; failure rates increase sharply above this threshold. 1

• Do not use nitrofurantoin for suspected pyelonephritis or when eGFR is <30 mL/min/1.73 m². 1

• Do not use oral fosfomycin for suspected upper-tract infection or pyelonephritis due to insufficient tissue penetration. 1

---

Acute Bacterial Sinusitis

First-Line Oral Antibiotics for Adults

Amoxicillin-clavulanate high-dose (2000 mg/125 mg twice daily or 875 mg/125 mg three times daily) is the preferred first-line agent for adults with mild disease who have not received antibiotics within the previous 4–6 weeks. This regimen provides adequate coverage for Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, which are the primary pathogens in acute bacterial rhinosinusitis. 2

• For patients with mild disease who have received antibiotics within the prior 4–6 weeks, or those with moderate disease (regardless of recent antibiotic exposure), use respiratory fluoroquinolones (gatifloxacin, levofloxacin, or moxifloxacin) or amoxicillin-clavulanate high-dose. 2

Penicillin Allergy Alternatives

• For patients with documented penicillin allergy, respiratory fluoroquinolones (levofloxacin 500–750 mg daily or moxifloxacin 400 mg daily) are the preferred alternatives. 2

• Doxycycline or a combination of trimethoprim-sulfamethoxazole plus clindamycin may be considered as second-line alternatives in penicillin-allergic patients, though efficacy is lower. 2

Treatment Duration

• The standard treatment duration for acute bacterial sinusitis is 10–14 days to ensure adequate eradication of S. pneumoniae and prevent complications. 2

Key Clinical Considerations

• Serious intracranial and extrasinus complications associated with acute bacterial rhinosinusitis usually arise secondary to S. pneumoniae infection, making adequate pneumococcal coverage essential in initial therapy. 2

• Gram-negative coverage for H. influenzae and M. catarrhalis cannot be ignored, particularly in patients with recent antibiotic exposure or moderate disease severity. 2

Common Pitfalls

• Do not use macrolides (azithromycin, clarithromycin) as first-line empiric therapy due to increasing S. pneumoniae resistance and lower predicted clinical outcomes. 2

• Do not use first-generation cephalosporins (cephalexin, cefadroxil) or cefaclor as first-line agents because they provide inadequate coverage for resistant S. pneumoniae. 2

• Recent antibiotic use is a major risk factor for infection caused by resistant pathogens; patients who have received antibiotics within 4–6 weeks require broader-spectrum coverage. 2